文献速递湿疹皮炎与荨麻疹

度普利尤单抗相关面部及颈部红斑的系统综述

Facial and neck erythema associated with dupilumab treatment: A systematic review.
PubMed 文献 · J Am Acad Dermatol · 2021-01-08

该系统综述汇总16项研究共101例度普利尤单抗相关面部或颈部红斑患者,52%基线有面部或颈部特应性皮炎累及,45%报告与原有皮炎不同的皮肤症状;57例有病程数据者中29例改善、4例消退、16例无应答、8例加重,11%因此停药。

要点

  • 度普利尤单抗治疗特应性皮炎可出现面部或颈部红斑,部分与原有皮炎表现不同。
  • 建议病因包括玫瑰痤疮、变应性接触性皮炎和头颈部皮炎。
  • 常用处理包括外用糖皮质激素、外用钙调神经磷酸酶抑制剂和抗真菌药。

核心结论

  • 部分接受度普利尤单抗的患者会出现不同于其寻常特应性皮炎症状的面部或颈部红斑。
  • 及时识别和经验性治疗可能减少患者痛苦及因该不良事件停用度普利尤单抗。

研究设计与样本

  • 系统综述,检索EMBASE和PubMed数据库,由两名独立评审者筛选相关研究并提取数据。
  • 共纳入16项研究、101例报告度普利尤单抗相关面部或颈部红斑的患者。

主要发现

  • 101例中52例(52%)基线有特应性皮炎面部或颈部累及。
  • 101例中45例(45%)报告与原有特应性皮炎不同的皮肤症状,可能提示不同病因。
  • 57例有不良事件病程数据的患者中,29例改善、4例消退、16例无应答、8例加重。
  • 101例中11例(11%)因该不良事件停用度普利尤单抗。

关键数值与推荐

  • 建议病因包括玫瑰痤疮、变应性接触性皮炎和头颈部皮炎。
  • 最常用治疗包括外用糖皮质激素、外用钙调神经磷酸酶抑制剂和抗真菌药。

临床怎么用

  • 对使用度普利尤单抗后出现面部或颈部红斑者,应识别其与原有特应性皮炎表现的不同。
  • 可考虑经验性治疗以减轻症状并避免因该不良事件停药。

局限性

  • 诊断检测有限。
  • 各研究数据收集和报告非标准化。
  • 依赖回顾性病例报告和病例系列。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Neither dupilumab-associated facial erythema nor neck erythema was reported in phase 3 clinical trials for the treatment of atopic dermatitis, but there have been a number of reports of patients developing this adverse event in clinical practice. OBJECTIVE: To outline all cases of reported dupilumab-associated facial or neck erythema to better characterize this adverse event, and identify potential etiologies and management strategies. METHODS: A search was conducted on EMBASE and PubMed databases. Two independent reviewers identified relevant studies for inclusion and performed data extraction. RESULTS: A total of 101 patients from 16 studies were reported to have dupilumab-associated facial or neck erythema. A total of 52 of 101 patients (52%) had baseline atopic dermatitis facial or neck involvement and 45 of 101 (45%) reported different cutaneous symptoms from preexisting atopic dermatitis, possibly suggesting a different etiology. Suggested etiologies included rosacea, allergic contact dermatitis, and head and neck dermatitis. Most commonly used treatments included topical corticosteroids, topical calcineurin inhibitors, and antifungal agents. In the 57 patients with data on the course of the adverse events, improvement was observed in 29, clearance in 4, no response in 16, and worsening in 8. A total of 11 of 101 patients (11%) discontinued dupilumab owing to this adverse event. LIMITATIONS: Limited diagnostic testing, nonstandardized data collection and reporting across studies, and reliance on retrospective case reports and case series. CONCLUSION: Some patients receiving dupilumab develop facial or neck erythema that differs from their usual atopic dermatitis symptoms. Prompt identification and empiric treatment may minimize distress and potential discontinuation of dupilumab owing to this adverse event.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Jo CE, Finstad A, Georgakopoulos JR, et al. Facial and neck erythema associated with dupilumab treatment: A systematic review. J Am Acad Dermatol. 2021. PMID: 33428978. doi:10.1016/j.jaad.2021.01.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。